P53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer

Nam Kyu Kim, Jae Kun Park, Kang Yong Lee, Woo Ik Yang, Seong Hyeon Yun, J. Sung, Jin Sik Min

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer is an important modality for curative resection, but tumors show wide spectrum response. The purpose of this study was to investigate any correlation among related genetic mutations, proliferative index, and tumor response after CCRT. Methods: This study included 23 patients with rectal cancer, who were preoperatively staged as at least T3 N1 or T4 (determined by transrectal ultrasonography and MRI). Enrolled patients were given 5-FU 450 mg/m2/day and leucovorin 20 mg/m2/day intravenously for 5 days during weeks 1 and 5 of radiotherapy (45-54 Gy). Surgical resection was performed 4 weeks after completion of the scheduled treatment. Tumor response was classified as CR (complete response), PR (partial response: 50% diminution of tumor volume and downstaging), and NR (no response). Paraffin-embedded tissue obtained before chemoradiotherapy was studied by immunohistochemical staining for p53, BCL-2, and Ki-67. The extent of tumor response was correlated with proliferative activity and was measured by immunostaining Ki-67 proliferative antigen and the expression of p53 and BCL-2 oncoproteins. Results: All patients were resectable. CR was obtained in 4 patients, PR in 10 patients, and NR in 9 patients. The p53 mutation was noted in 16 patients: NR in 5 patients, PR in 9 patients, and CR in 2 patients (P = .638). BCL-2 expression was noted in 11 patients: NR in 4 patients, PR in 3 patients, and CR in 4 patients (P = .799). The Ki-67 labeling index was NR: 615.4 ± 47.2; PR: 663.2 ± 20.4; and CR: 765.5 ± 58.3 (CR + PR vs. NR, P = .029). Conclusions: Immunohistochemical expression of p53 and BCL-2 does not correlate with tumor response after CCRT, but Ki-67 labeling may be a useful parameter for radiosensitive tumors selected for CCRT.

Original languageEnglish
Pages (from-to)418-424
Number of pages7
JournalAnnals of Surgical Oncology
Volume8
Issue number5
DOIs
Publication statusPublished - 2001 Jan 1

Fingerprint

Chemoradiotherapy
Rectal Neoplasms
Neoplasms
Ki-67 Antigen
Puromycin
Mutation
Leucovorin
Oncogene Proteins
Tumor Burden
Fluorouracil
Paraffin
Ultrasonography
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Kim, Nam Kyu ; Park, Jae Kun ; Lee, Kang Yong ; Yang, Woo Ik ; Yun, Seong Hyeon ; Sung, J. ; Min, Jin Sik. / P53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. In: Annals of Surgical Oncology. 2001 ; Vol. 8, No. 5. pp. 418-424.
@article{c0d78e5992104fdbad5cfb2287350994,
title = "P53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer",
abstract = "Background: Concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer is an important modality for curative resection, but tumors show wide spectrum response. The purpose of this study was to investigate any correlation among related genetic mutations, proliferative index, and tumor response after CCRT. Methods: This study included 23 patients with rectal cancer, who were preoperatively staged as at least T3 N1 or T4 (determined by transrectal ultrasonography and MRI). Enrolled patients were given 5-FU 450 mg/m2/day and leucovorin 20 mg/m2/day intravenously for 5 days during weeks 1 and 5 of radiotherapy (45-54 Gy). Surgical resection was performed 4 weeks after completion of the scheduled treatment. Tumor response was classified as CR (complete response), PR (partial response: 50{\%} diminution of tumor volume and downstaging), and NR (no response). Paraffin-embedded tissue obtained before chemoradiotherapy was studied by immunohistochemical staining for p53, BCL-2, and Ki-67. The extent of tumor response was correlated with proliferative activity and was measured by immunostaining Ki-67 proliferative antigen and the expression of p53 and BCL-2 oncoproteins. Results: All patients were resectable. CR was obtained in 4 patients, PR in 10 patients, and NR in 9 patients. The p53 mutation was noted in 16 patients: NR in 5 patients, PR in 9 patients, and CR in 2 patients (P = .638). BCL-2 expression was noted in 11 patients: NR in 4 patients, PR in 3 patients, and CR in 4 patients (P = .799). The Ki-67 labeling index was NR: 615.4 ± 47.2; PR: 663.2 ± 20.4; and CR: 765.5 ± 58.3 (CR + PR vs. NR, P = .029). Conclusions: Immunohistochemical expression of p53 and BCL-2 does not correlate with tumor response after CCRT, but Ki-67 labeling may be a useful parameter for radiosensitive tumors selected for CCRT.",
author = "Kim, {Nam Kyu} and Park, {Jae Kun} and Lee, {Kang Yong} and Yang, {Woo Ik} and Yun, {Seong Hyeon} and J. Sung and Min, {Jin Sik}",
year = "2001",
month = "1",
day = "1",
doi = "10.1245/aso.2001.8.5.418",
language = "English",
volume = "8",
pages = "418--424",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

P53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. / Kim, Nam Kyu; Park, Jae Kun; Lee, Kang Yong; Yang, Woo Ik; Yun, Seong Hyeon; Sung, J.; Min, Jin Sik.

In: Annals of Surgical Oncology, Vol. 8, No. 5, 01.01.2001, p. 418-424.

Research output: Contribution to journalArticle

TY - JOUR

T1 - P53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer

AU - Kim, Nam Kyu

AU - Park, Jae Kun

AU - Lee, Kang Yong

AU - Yang, Woo Ik

AU - Yun, Seong Hyeon

AU - Sung, J.

AU - Min, Jin Sik

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: Concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer is an important modality for curative resection, but tumors show wide spectrum response. The purpose of this study was to investigate any correlation among related genetic mutations, proliferative index, and tumor response after CCRT. Methods: This study included 23 patients with rectal cancer, who were preoperatively staged as at least T3 N1 or T4 (determined by transrectal ultrasonography and MRI). Enrolled patients were given 5-FU 450 mg/m2/day and leucovorin 20 mg/m2/day intravenously for 5 days during weeks 1 and 5 of radiotherapy (45-54 Gy). Surgical resection was performed 4 weeks after completion of the scheduled treatment. Tumor response was classified as CR (complete response), PR (partial response: 50% diminution of tumor volume and downstaging), and NR (no response). Paraffin-embedded tissue obtained before chemoradiotherapy was studied by immunohistochemical staining for p53, BCL-2, and Ki-67. The extent of tumor response was correlated with proliferative activity and was measured by immunostaining Ki-67 proliferative antigen and the expression of p53 and BCL-2 oncoproteins. Results: All patients were resectable. CR was obtained in 4 patients, PR in 10 patients, and NR in 9 patients. The p53 mutation was noted in 16 patients: NR in 5 patients, PR in 9 patients, and CR in 2 patients (P = .638). BCL-2 expression was noted in 11 patients: NR in 4 patients, PR in 3 patients, and CR in 4 patients (P = .799). The Ki-67 labeling index was NR: 615.4 ± 47.2; PR: 663.2 ± 20.4; and CR: 765.5 ± 58.3 (CR + PR vs. NR, P = .029). Conclusions: Immunohistochemical expression of p53 and BCL-2 does not correlate with tumor response after CCRT, but Ki-67 labeling may be a useful parameter for radiosensitive tumors selected for CCRT.

AB - Background: Concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer is an important modality for curative resection, but tumors show wide spectrum response. The purpose of this study was to investigate any correlation among related genetic mutations, proliferative index, and tumor response after CCRT. Methods: This study included 23 patients with rectal cancer, who were preoperatively staged as at least T3 N1 or T4 (determined by transrectal ultrasonography and MRI). Enrolled patients were given 5-FU 450 mg/m2/day and leucovorin 20 mg/m2/day intravenously for 5 days during weeks 1 and 5 of radiotherapy (45-54 Gy). Surgical resection was performed 4 weeks after completion of the scheduled treatment. Tumor response was classified as CR (complete response), PR (partial response: 50% diminution of tumor volume and downstaging), and NR (no response). Paraffin-embedded tissue obtained before chemoradiotherapy was studied by immunohistochemical staining for p53, BCL-2, and Ki-67. The extent of tumor response was correlated with proliferative activity and was measured by immunostaining Ki-67 proliferative antigen and the expression of p53 and BCL-2 oncoproteins. Results: All patients were resectable. CR was obtained in 4 patients, PR in 10 patients, and NR in 9 patients. The p53 mutation was noted in 16 patients: NR in 5 patients, PR in 9 patients, and CR in 2 patients (P = .638). BCL-2 expression was noted in 11 patients: NR in 4 patients, PR in 3 patients, and CR in 4 patients (P = .799). The Ki-67 labeling index was NR: 615.4 ± 47.2; PR: 663.2 ± 20.4; and CR: 765.5 ± 58.3 (CR + PR vs. NR, P = .029). Conclusions: Immunohistochemical expression of p53 and BCL-2 does not correlate with tumor response after CCRT, but Ki-67 labeling may be a useful parameter for radiosensitive tumors selected for CCRT.

UR - http://www.scopus.com/inward/record.url?scp=0035005156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035005156&partnerID=8YFLogxK

U2 - 10.1245/aso.2001.8.5.418

DO - 10.1245/aso.2001.8.5.418

M3 - Article

C2 - 11407516

AN - SCOPUS:0035005156

VL - 8

SP - 418

EP - 424

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -